Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1

ClinicalTrials.gov ID: NCT00678886

Public ClinicalTrials.gov record NCT00678886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND

Study identification

NCT ID
NCT00678886
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
272 participants

Conditions and interventions

Interventions

  • otelixizumab infusion plus physician determined standard of care Biological
  • placebo infusion plus physician determined standard of care Biological

Biological

Eligibility (public fields only)

Age range
12 Years to 45 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 28, 2008
Primary completion
Jan 30, 2012
Completion
Jan 30, 2012
Last update posted
Oct 2, 2017

2008 – 2012

United States locations

U.S. sites
67
U.S. states
31
U.S. cities
61
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Costa Mesa California 92626
GSK Investigational Site Los Angeles California 90033
GSK Investigational Site Orange California 92868
GSK Investigational Site Riverside California 92506
GSK Investigational Site Santa Ana California 92705
GSK Investigational Site Torrance California 90502
GSK Investigational Site Walnut Creek California 94598
GSK Investigational Site Aurora Colorado 80045
GSK Investigational Site Washington D.C. District of Columbia 20037
GSK Investigational Site Boca Raton Florida 33486
GSK Investigational Site Jupiter Florida 33458
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Miami Florida 33169
GSK Investigational Site Orlando Florida 32803
GSK Investigational Site Orlando Florida 32835
GSK Investigational Site Pembroke Pines Florida 33024
GSK Investigational Site Trinity Florida 34655
GSK Investigational Site Winter Park Florida 32789
GSK Investigational Site Atlanta Georgia 30309
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Honolulu Hawaii 96813
GSK Investigational Site Boise Idaho 83702
GSK Investigational Site Idaho Falls Idaho 83404-7542
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Indianapolis Indiana 46260
GSK Investigational Site Atlanta Kansas 21287
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site Worcester Massachusetts 01655-0002
GSK Investigational Site Detroit Michigan 48201
GSK Investigational Site Kalamazoo Michigan 49048
GSK Investigational Site Gulfport Mississippi 39501
GSK Investigational Site Columbia Missouri 65212
GSK Investigational Site Kansas City Missouri 64106
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site Neptune City New Jersey 07753
GSK Investigational Site Buffalo New York 14209
GSK Investigational Site Mineola New York 11501
GSK Investigational Site New York New York 10032
GSK Investigational Site Rochester New York 14642
GSK Investigational Site Durham North Carolina 27713
GSK Investigational Site Columbus Ohio 43205
GSK Investigational Site Columbus Ohio 43210
GSK Investigational Site Dayton Ohio 45415-2560
GSK Investigational Site Mentor Ohio 44060
GSK Investigational Site Tulsa Oklahoma 74136-8303
GSK Investigational Site Eugene Oregon 97401
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Langhorne Pennsylvania 19047
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site Charleston South Carolina 29425-6240
GSK Investigational Site Rapid City South Dakota 57701
GSK Investigational Site Chattanooga Tennessee 37403
GSK Investigational Site Memphis Tennessee 38119
GSK Investigational Site Nashville Tennessee 37212
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site Dallas Texas 75390
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Hurst Texas 76054
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Schertz Texas 782154
GSK Investigational Site Ogden Utah 84403
GSK Investigational Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00678886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 2, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00678886 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →